Related Experiment Video
Updated: Jan 10, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer
Semih Alpsoy1,2, Osman Ugur Sezerman3
1Department of Molecular Biotechnology, Türkisch-Deutsche Universität, Istanbul, Turkey.
Abstract:
Drug resistance remains one of the primary challenges in effective cancer therapy. In this study, we employed a deep neural network (DNN)-based transfer learning (TL) approach to predict drug response and uncover drug resistance mechanisms. We integrated gene expression, somatic mutation, and copy number aberration (CNA) data with drug response profiles using multi-omics integration (MI). We used the Genomics of Drug Sensitivity in Cancer (GDSC) data for training and incorporated drugs with same pathways into the training models. We then evaluated drug response predictions on independent in-vivo PDX Encyclopedia (PDX) and ex-vivo the Cancer Genome Atlas (TCGA) datasets. In addition, we conducted pathway enrichment analyses to elucidate the mechanisms underlying drug resistance for paclitaxel, 5-fluorouracil (5-FU), gemcitabine, and cetuximab. We also applied Fisher's exact test (FET) to assess potential associations between drug resistance and the presence of mutations or CNAs. Our pan-drug models outperformed other methods based on the area under the precision-recall curve (AUCPR). Our pathway enrichment analyses revealed LDHB-mediated pyruvate metabolism and FYN-mediated focal adhesion might have pivotal roles in paclitaxel resistance, while PINK1-mediated mitophagy might be critical in 5-FU resistance. In addition to transcriptional activation, FET suggested that CNAs in LDHB and PINK1 may also be associated with resistance to paclitaxel and 5-FU, respectively. Furthermore, enrichment results for paclitaxel and cetuximab indicated shared resistance mechanisms between the two drugs. Importantly, our findings are consistent with prior experimental studies, providing literature-based validation of our results. Overall, our DNN-based TL approach achieved strong predictive performance across PDX & TCGA datasets and enrichment analyses provided valuable biological insights into drug resistance mechanisms.
Insights
This study uses deep learning and multi-omics data to predict cancer drug response and identify resistance mechanisms. The approach successfully predicted drug sensitivity and revealed key pathways involved in resistance for several common cancer drugs.
Area of Science:
- Computational biology
- Genomics
- Cancer research
Background:
- Drug resistance is a major obstacle in cancer therapy.
- Predicting drug response and understanding resistance mechanisms are crucial for personalized medicine.
Purpose of the Study:
- To develop a deep neural network (DNN)-based transfer learning (TL) approach for predicting cancer drug response.
- To uncover molecular mechanisms underlying drug resistance using multi-omics integration (MI).
Main Methods:
- Integrated gene expression, somatic mutation, and copy number aberration (CNA) data with drug response profiles.
- Employed a DNN-based TL approach trained on Genomics of Drug Sensitivity in Cancer (GDSC) data.
- Validated predictions on independent in-vivo PDX Encyclopedia (PDX) and ex-vivo Cancer Genome Atlas (TCGA) datasets.
- Conducted pathway enrichment analyses and Fisher's exact test (FET) to identify resistance mechanisms and associations with mutations/CNAs.
Main Results:
- The pan-drug models achieved superior performance in predicting drug response (AUCPR).
- Identified LDHB-mediated pyruvate metabolism and FYN-mediated focal adhesion in paclitaxel resistance, and PINK1-mediated mitophagy in 5-FU resistance.
- Found associations between CNAs in LDHB and PINK1 and resistance to paclitaxel and 5-FU, respectively.
- Discovered shared resistance mechanisms between paclitaxel and cetuximab.
Conclusions:
- The DNN-based TL approach demonstrates strong predictive power for drug response across diverse datasets.
- Pathway enrichment analyses provide significant biological insights into complex drug resistance mechanisms.
- Findings are consistent with existing literature, validating the model's utility in cancer research.
More Related Videos
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...